MaxCyte Inc (MXCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MaxCyte Inc (MXCT) has a cash flow conversion efficiency ratio of -0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.46 Million) by net assets ($180.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MXCT market cap for the company's overall valuation and market capitalisation.
MaxCyte Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how MaxCyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MaxCyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MaxCyte Inc ranked by their cash flow conversion efficiency. See MXCT operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Casino Guichard Perrachon SA
PA:CO
|
0.071x |
|
Asahimas Flat Glass Tbk
JK:AMFG
|
-0.002x |
|
Wanbury Limited
NSE:WANBURY
|
-0.053x |
|
Berenson Acquisition Corp I
NYSE MKT:BACA
|
1.396x |
|
Kothari Petrochemicals Limited
NSE:KOTHARIPET
|
0.130x |
|
Peace Acquisition Corp Ordinary Shares
NASDAQ:PECE
|
-0.003x |
|
Adicet Bio Inc
NASDAQ:ACET
|
-0.165x |
|
Tongyang
KO:001520
|
0.020x |
Annual Cash Flow Conversion Efficiency for MaxCyte Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of MaxCyte Inc from 2012 to 2024. View MaxCyte Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $206.25 Million | $-27.61 Million | -0.134x | -43.31% |
| 2023-12-31 | $232.17 Million | $-21.69 Million | -0.093x | -60.47% |
| 2022-12-31 | $253.97 Million | $-14.78 Million | -0.058x | -43.29% |
| 2021-12-31 | $262.90 Million | $-10.68 Million | -0.041x | +84.63% |
| 2020-12-31 | $33.23 Million | $-8.78 Million | -0.264x | +59.16% |
| 2019-12-31 | $13.60 Million | $-8.80 Million | -0.647x | +24.21% |
| 2018-12-31 | $12.28 Million | $-10.49 Million | -0.854x | -72.92% |
| 2017-12-31 | $19.60 Million | $-9.68 Million | -0.494x | -7.51% |
| 2016-12-31 | $5.08 Million | $-2.33 Million | -0.459x | -884.44% |
| 2015-12-31 | $-3.08 Million | $-180.50K | 0.059x | -94.99% |
| 2014-12-31 | $-1.65 Million | $-1.93 Million | 1.169x | +223.42% |
| 2013-12-31 | $-1.54 Million | $-557.80K | 0.361x | -89.96% |
| 2012-12-31 | $-590.70K | $-2.13 Million | 3.599x | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more